Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ADR ARGX

Healthcare Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an... see more

Recent & Breaking News (NDAQ:ARGX)

argenx Announces Planned Transition of Chief Operating Officer

GlobeNewswire March 2, 2023

argenx Appoints Steve Krognes to Board of Directors

GlobeNewswire February 27, 2023

argenx to Present at Upcoming Investor Conferences

GlobeNewswire February 27, 2023

argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023

GlobeNewswire February 23, 2023

argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod

GlobeNewswire January 27, 2023

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

GlobeNewswire January 16, 2023

argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline

GlobeNewswire January 9, 2023

argenx to Present at 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2023

argenx Appoints Ana Cespedes to Board of Directors

GlobeNewswire December 12, 2022

argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia

GlobeNewswire December 10, 2022

argenx Enters Into Agreement To Acquire Priority Review Voucher

GlobeNewswire November 30, 2022

argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

GlobeNewswire November 22, 2022

argenx to Present at Upcoming Investor Conferences

GlobeNewswire November 7, 2022

argenx Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire October 27, 2022

argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022

GlobeNewswire October 20, 2022

argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

GlobeNewswire September 21, 2022

argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings

GlobeNewswire September 21, 2022

argenx Appoints Camilla Sylvest to Board of Directors

GlobeNewswire September 8, 2022

argenx to Present at Wells Fargo Healthcare Conference

GlobeNewswire August 31, 2022

argenx Announces European Commission Approval of VYVGART(TM) (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

GlobeNewswire August 11, 2022